Early cancer screening startup Grail could raise more than $1 billion in a series B round, making it in one of the largest financings in med-tech history. Grail said the funding would be used to develop a blood-based test for cancer screening. In addition, part of the funding would be used to repurchase a portion of Illumina Inc.'s stake in Grail.